11 completed, 5 terminated, 2 active not recruiting. 12 Phase 1, 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 8, Terminated 3, Active not recruiting 1 |
| Phase 2 | 7 | Completed 3, Terminated 3, Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow dinaciclib: new trials by email Literature Review of dinaciclib trials Research Report on dinaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Venetoclax, Dinaciclib - Cancer - Acute Myeloid Leukemia | Phase 1 | Terminated | AbbVie | 48 | 2018-07-23 | 2022-12-30 |
| Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Dinaciclib, Pembrolizumab - Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Completed | Jo Chien | 32 | 2016-12-28 | 2022-09-21 |
| Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) pembrolizumab, dinaciclib - rrCLL, rrMM | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 75 | 2016-03-29 | 2021-03-01 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2013-01-15 | 2017-08-22 |
| Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Bortezomib, Dexamethasone, Dinaciclib - Recurrent Plasma Cell Myeloma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-12-19 | 2018-05-11 |
| A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) Dinaciclib, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Completed | Merck Sharp & Dohme LLC | 5 | 2012-10-01 | 2015-02-10 |
| Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer Dinaciclib, Epirubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2012-08-21 | 2018-03-30 |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) Dinaciclib, Ofatumumab - Chronic Lymphocytic Leukemia (CLL) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 44 | 2012-08-01 | 2017-02-23 |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-01-01 | 2018-03-15 |
| Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors Dinaciclib, Veliparib - Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 121 | 2011-11-11 | 2026-08-03 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma dinaciclib, pharmacological study, laboratory biomarker analysis - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2009-09-01 | 2017-04-04 |
| Dinaciclib in Treating Patients With Stage IV Melanoma Dinaciclib - Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2009-07-01 | 2026-09-14 |
| Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma dinaciclib, laboratory biomarker analysis - Refractory Multiple Myeloma | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2009-07-01 | 2014-06-18 |
| SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) SCH 727965, Bortezomib, Alemtuzumab - Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 8 | 2009-03-01 | 2015-08-07 |
| SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) SCH 727965, Gemtuzumab ozogamicin - Leukemia, Myeloid, Acute, Lymphoblastic Leukemia, Acute | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 29 | 2009-01-01 | 2015-02-04 |
| SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) SCH 727965, Capecitabine, Erlotinib - Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck Sharp & Dohme LLC | 97 | 2008-07-01 | 2015-08-05 |
| Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) SCH 727965, Aprepitant, Ondansetron - Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Merck Sharp & Dohme LLC | 81 | 2006-10-11 | 2017-10-23 |
| Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) SCH 727965 - Solid Tumors, Lymphoma, Non-Hodgkin | Phase 1 | Completed | Merck Sharp & Dohme LLC | 123 | 2006-08-01 | 2015-04-20 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Multiple Myeloma (4) · Breast Neoplasms (3) · Leukemia, Myeloid, Acute (2) · Lymphoma, Non-Hodgkin (2) · Melanoma (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, B-Cell (1) · Leukemia, Prolymphocytic (1) · Lymphoma, Mantle-Cell (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Merck Sharp & Dohme LLC (8) · National Cancer Institute (NCI) (8) · AbbVie (1) · Jo Chien (1)
United States (10) · Australia (1) · Canada (1) · Singapore (1) · Spain (1)
Shaji Kumar (2) · A. Jo Chien, MD (1) · Christopher D Lao (1) · Frank Hodi (1) · Geoffrey I Shapiro (1) · Kerry Rogers, MD (1) · Nilofer Azad (1) · Stacy Moulder (1)
PMID 23053255, PMID 23949430, PMID 24131779, PMID 24388167, PMID 24393852, PMID 25217392, PMID 25395429, PMID 25931518, PMID 25947565, PMID 28126927, PMID 28859059, PMID 34972202, PMID 39342463
P30CA006516 (2), P30CA015083 (2), U01CA062490 (2), UM1CA186716 (2), 2017 (1), N01CM00070 (1), N01CM62205 (1), N01CM62207 (1), P30CA006973 (1), P30CA016058 (1), P30CA016672 (1), P50CA140158 (1), R01CA090687 (1), R01CA152228 (1), R01CA167511 (1)